At its Oct. 12, 2026 semiannual results briefing, Zhijiang Biological said overseas markets are a strategic priority. In 1H2026 the company secured seven new international certifications. With ongoing deliveries of overseas orders, expanded CE/FDA co

2026-10-12

At its Oct. 12, 2026 semiannual results briefing, Zhijiang Biological said overseas markets are a strategic priority. In 1H2026 the company secured seven new international certifications. With ongoing deliveries of overseas orders, expanded CE/FDA coverage and deeper distribution channels, it expects overseas revenue to increase gradually, targeting Europe, Africa, the Middle East and Southeast Asia.